All Stories

  1. Comparative analysis of salivary microbiota in diabetic and non-diabetic individuals of North India using metagenomics
  2. SARS-CoV-2 Infection, Inflammation, Immunonutrition, and Pathogenesis of COVID-19
  3. Neuroprotective Effect of Levetiracetam in Combination with Berberine on Scopolamine Induced-Cognitive Impairment in Mice: A Behavioral and Biochemical Approach
  4. Transforming clinical virology with AI, machine learning and deep learning: a comprehensive review and outlook
  5. Understanding HIV-associated neurocognitive and neurodegenerative disorders (neuroAIDS): enroute to achieve the 95-95-95 target and sustainable development goal for HIV/AIDS response
  6. Tracking the COVID-19 vaccines: The global landscape
  7. Antiviral and anti‐inflammatory activity of natural compounds against Japanese encephalitis virus via inhibition of NS5 protein and regulation of key immune and inflammatory signaling pathways
  8. Antiviral and anti-inflammatory activity of novel belladonna formulation against Japanese encephalitis virus via inhibition of p65 nuclear translocation and TNF-α mediated NF-kB signaling
  9. Infectious Diseases Annual Volume 2022
  10. Fabrication and Evaluation of Basil Essential Oil-Loaded Halloysite Nanotubes in Chitosan Nanocomposite Film and Its Application in Food Packaging
  11. Pre-clinical investigation of protective effect of nutraceutical D-glucosamine on TNBS-induced colitis
  12. Tracing the origin of Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2): A systematic review and narrative synthesis
  13. Re‐emerging human monkeypox: A major public‐health debacle
  14. Trends in Molecular Aspects and Therapeutic Applications of Drug Repurposing for Infectious Diseases
  15. Introductory Chapter: High-Throughput Screening - A New Tool for Precision Medicine
  16. High-Throughput Screening for Drug Discovery toward Infectious Diseases: Options and Challenges
  17. Pneumonia
  18. Progress and Challenges Toward Generation and Maintenance of Long-Lived Memory T Lymphocyte Responses During COVID-19
  19. Chikungunya Virus - A Growing Global Public Health Threat
  20. Association between Adaptive Evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein and Geographically Distinct Virus Epidemiology During the Initial Wave of the Coronavirus Disease 2019 Pandemic
  21. Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus‐2 Omicron Variant of Concern
  22. Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective
  23. Environmental Nanomedicine
  24. Microbicidal Nanoparticles
  25. Epstein-Barr Virus - New Trends
  26. Structural and molecular perspectives of SARS-CoV-2
  27. Therapeutic approaches for SARS-CoV-2 infection
  28. Innate Immunity in Health and Disease
  29. Pathogenesis and Host Immune Response during Japanese Encephalitis Virus Infection
  30. Multi-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations
  31. Wound Healing Activity of a Novel Formulation SKRIN via Induction of Cell Cycle Progression and Inhibition of PCNA–p21 Complex Interaction Leading to Cell Survival and Proliferation
  32. Artificial Intelligence in Mental Healthcare During COVID-19 Pandemic
  33. Artificial Intelligence-Enabled Prognosis Technologies for SARS-CoV-2/COVID-19
  34. Use of Mobile Phone Apps for Contact Tracing to Control the COVID-19 Pandemic: A Literature Review
  35. Role of metabolomics in identifying cardiac hypertrophy: an overview of the past 20 years of development and future perspective
  36. Applications of Artificial Intelligence in COVID-19
  37. Zika Virus Disease: Progress and Prospects
  38. An Ophthalmological update for air-travellers during COVID-19
  39. The relevance of digital mental healthcare during COVID-19: Need for innovations
  40. Chasing COVID-19 through SARS-CoV-2 spike glycoprotein
  41. COVID-19 in the elderly people and advances in vaccination approaches
  42. Plant-based vaccines and antibodies to combat COVID-19: current status and prospects
  43. Recombinant vaccines for COVID-19
  44. Dengue Fever in a One Health Perspective
  45. Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection
  46. Antiviral Activity of Belladonna During Japanese Encephalitis Virus Infection via Inhibition of Microglia Activation and Inflammation Leading to Neuronal Cell Survival
  47. Mental illnesses among COVID-19 patients: Possible immunological underpinnings
  48. Viral Hepatitis E and Chronicity: A Growing Public Health Concern
  49. COVID-19: benefits and risks of passive immunotherapeutics
  50. Calcarea carbonica treatment rescues lipopolysaccharide-induced inflammatory response in human mononuclear cells via downregulation of inducible cyclooxygenase pathway
  51. Dark Classics in Chemical Neuroscience: An Evidence-Based Systematic Review of Belladonna
  52. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives
  53. Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor
  54. Hepatitis B and C
  55. High sensitivity C-reactive protein level in cerebrovascular accident
  56. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)
  57. Comparative analysis of Hemagglutinin of 2013 H3N2 Influenza A virus Indicates its Evolution from 1968 H3N2 Pandemic Influenza A virus
  58. Use of Mobile Phone Apps for Contact Tracing to Control the COVID-19 Pandemic: A Literature Review
  59. Next-Generation Rapid Advanced Molecular Diagnostics of COVID-19 by CRISPR-Cas
  60. A demographic prevalence of β Thalassemia carrier and other hemoglobinopathies in adolescent of Tharu population
  61. Animal Flaviviruses
  62. COVID-19: An Ophthalmological Update
  63. Classical Coronaviruses
  64. Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19)
  65. Contemporary vaccine approaches and role of next-generation vaccine adjuvants in managing viral diseases
  66. Coping with Mental Health Challenges During COVID-19
  67. Coronavirus Disease 2019 (COVID-19)
  68. Coronavirus Infection Among Children and Adolescents
  69. Correction to: Transmission Cycle of SARS-CoV and SARS-CoV-2
  70. Current Advances in Nanotechnology and Medicine
  71. Current Insight into the Novel Coronavirus Disease 2019 (COVID-19)
  72. Diagnostic Strategies for COVID-19 and other Coronaviruses
  73. Emergence and Reemergence of Severe Acute Respiratory Syndrome (SARS) Coronaviruses
  74. Futuristic Technologies for Advanced Detection, Prevention, and Control of COVID-19
  75. Global Trends in Epidemiology of Coronavirus Disease 2019 (COVID-19)
  76. Host Immune Response and Immunobiology of Human SARS-CoV-2 Infection
  77. Laboratory Diagnosis of Novel Coronavirus Disease 2019 (COVID-19) Infection
  78. Modern Approaches in Nanomedicine for NeuroAIDS and CNS Drug Delivery
  79. Morphology, Genome Organization, Replication, and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
  80. NanoBioMedicine
  81. Nanotoxicology in Medicine
  82. Negative COVID-19 Test: What Next?
  83. Nipah Virus
  84. Opportunities in Clinical Translation and Commercialization of Nanomedicine
  85. Pandemic Influenza A Virus (pH1N1)
  86. Preparing Children for Pandemics
  87. Preparing for the Perpetual Challenges of Pandemics of Coronavirus Infections with Special Focus on SARS-CoV-2
  88. Prevention and Control Strategies for SARS-CoV-2 Infection
  89. Radiological Perspective of the Novel Coronavirus Disease 2019 (COVID-19)
  90. Therapeutic Development and Drugs for the Treatment of COVID-19
  91. Transmission Cycle of SARS-CoV and SARS-CoV-2
  92. Water-Associated Infectious Diseases
  93. Malaria
  94. Current Topics in Neglected Tropical Diseases
  95. The Global Distribution and Burden of Dengue and Japanese Encephalitis Co-Infection in Acute Encephalitis Syndrome
  96. Complementary and Alternative Medicine Treatments of Water-Associated Infectious Diseases in Alliance with Conventional Medicine Treatments
  97. Conventional Treatments of Water-Associated Infectious Diseases
  98. Emerging and Re-emerging Water-Associated Infectious Diseases
  99. Epidemiology of Water-Associated Infectious Diseases
  100. Etiological Agents of Water-Associated Infectious Diseases
  101. Evolution and Interplay of Water-Associated Human Pathogens
  102. Global Strategies and Schemes for Preventing Water-Associated Infectious Diseases
  103. Hazards Associated with Contaminated Water
  104. Impact of Climate Change on Water-Associated Infectious Diseases
  105. Introduction to Water-Associated Infectious Diseases
  106. Novel Approaches for Detecting Water-Associated Pathogens
  107. Treatment of Water to Prevent Water-Associated Infectious Diseases
  108. Correlation of Cytogenetic, Molecular and Clinical Findings in Thalassemia Patients at a Tertiary Care Hospital
  109. Hydroxyapatite–collagen augments osteogenic differentiation of dental pulp stem cells
  110. Cytogenetic Analysis of Down Syndrome Patients in Eastern Uttar Pradesh.
  111. Current Perspectives in Human Papillomavirus
  112. Recent Advances in Human Papillomavirus Infection and Management
  113. Pathogen-associated acute encephalitis syndrome: therapeutics and management
  114. Zika virus disease in India - Update October 2018
  115. Introductory Chapter: Human Influenza A Virus Infection - Global Prevalence, Prevention, Therapeutics, and Challenges
  116. Influenza - Therapeutics and Challenges
  117. Global Perspective of Novel Therapeutic Strategies for the Management of NeuroAIDS
  118. Introductory Chapter: Neglected Tropical Waterborne Infectious Diseases - Strategies for Mitigation
  119. Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements
  120. Complementary and alternative medicine in alliance with conventional medicine for dengue therapeutics and prevention
  121. Reducing the Global Burden of Dengue: Steps toward Preventive Methods
  122. Mesenchymal stem cells in regenerative medicine: a new paradigm for degenerative bone diseases
  123. Current Advances in Zika Virus Transmission: Urgency for Effective Therapeutics and Prevention
  124. Complementary and alternative medicine in alliance with conventional medicine for influenza therapeutics and prevention
  125. Proof and Concepts in Rapid Diagnostic Tests and Technologies
  126. Introductory Chapter: Serum Components as Rapid Diagnostic Biomakers During Flavivirus Infection
  127. Emerging Zika virus disease: a public health emergency of global concern
  128. Advances in Molecular Retrovirology
  129. Molecular Biology and Pathogenesis of Retroviruses
  130. Zika virus outbreak: an overview of the experimental therapeutics and treatment
  131. Investigation of Neuropathogenesis in HIV-1 Clade B and C Infection Associated with IL-33 and ST2 Regulation
  132. Interactive effects of cocaine on HIV infection: implication in HIV-associated neurocognitive disorder and neuroAIDS
  133. Japanese encephalitis: a major public-health debacle
  134. Japanese Encephalitis: A Neglected Viral Disease and Its Impact on Global Health
  135. Trends in Infectious Diseases
  136. CURRENT SCENARIO OF THERAPEUTICS FOR EBOLA VIRUS DISEASE
  137. An insight into flaviviral budding: a need to know more
  138. Towards nanomedicines for neuroAIDS
  139. Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder
  140. Current Scenario of Antiviral Drugs for Japanese Encephalitis
  141. Cocaine Enhances HIV-1 Infectivity in Monocyte Derived Dendritic Cells by Suppressing microRNA-155
  142. Latency, persistence and reactivation of Japanese encephalitis virus
  143. Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study
  144. Current Perspectives in HIV Infection
  145. NeuroAIDS: Mechanisms, Causes, Prevalence, Diagnostics and Social Issues
  146. Latest trends in drugs of abuse – HIV infection and neuroAIDS
  147. Japanese Encephalitis Virus: The Complex Biology of an Emerging Pathogen
  148. Influenza A(H1N1)pdm09 virus: therapeutics and challenges
  149. A Global Perspective on HIV/AIDS
  150. Nanotherapeutics: emerging competent technology in neuroAIDS and CNS drug delivery
  151. Modulation of HIV pathogenesis and T-cell signaling by HIV-1 Nef
  152. Targeting Strategies for Human Immunodeficiency Virus: A Combinatorial Approach
  153. HIV-1 Nef: hacker of the host cell
  154. Rendezvous with Tat: Transactivator of Transcription during Human Immunodeficiency Virus Pathogenesis
  155. Japanese Encephalitis: A Persistent Threat
  156. The Intolerable Burden of Chikungunya: What’s New, What’s Needed?
  157. Interactive Effects of Morphine on HIV Infection: Role in HIV-Associated Neurocognitive Disorder
  158. JAPANESE ENCEPHALITIS VIRUS: AN EMERGING PATHOGEN
  159. Japanese Encephalitis: An Emerging and Spreading Arbovirosis
  160. HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: Implication for HIV-associated neurocognitive disorder (HAND)
  161. Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS
  162. Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: Implications for HIV-1–associated neurocognitive disorder
  163. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors
  164. Escalation of Japanese encephalitis in India: Evidence from 2005 viral encephalitis outbreak and appraisal of niceties
  165. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors
  166. Structural and antigenic variance between novel influenza A/H1N1/2009 and influenza A/H1N1/2008 viruses
  167. Swine flu: Influenza A/H1N1 2009: the unseen and unsaid
  168. Trend of Japanese encephalitis in North India: evidence from thirty-eight acute encephalitis cases and appraisal of niceties
  169. Advances in antiviral drug discovery and development: Part II: Advancements in antiviral drug development
  170. Controversial role of smallpox on historical positive selection at the CCR5 chemokine gene (CCR5-Δ32)
  171. Paromomycin: Uptake and resistance in Leishmania donovani
  172. Advances in antiviral drug discovery and development: Part I: Advancements in antiviral drug discovery
  173. The Latitude Wise Prevalence of the CCR5-Δ32-HIV Resistance Allele in India
  174. Japanese encephalitis: perspectives and new developments
  175. Enzymatic and Structural Characterisation of Amphinase, a Novel Cytotoxic Ribonuclease from Rana pipiens Oocytes
  176. Re-emergence of the knotty chikungunya virus: facts, fear or fiction
  177. Differential HIV-1 replication in neonatal and adult blood mononuclear cells is influenced at the level of HIV-1 gene expression
  178. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis
  179. Reply to 'Encephalitis outbreak finds Indian officials unprepared'
  180. A Heterologous Prime‐Boost Vaccination Regimen Using ORFF DNA and Recombinant ORFF Protein Confers Protective Immunity against Experimental Visceral Leishmaniasis
  181. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen
  182. ONCONASE ® and Its Therapeutic Potential
  183. Inhibition of Japanese Encephalitis Virus Infection by Diethyldithiocarbamate is Independent of its Antioxidant Potential
  184. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani
  185. Alteration in plasma glucose levels in Japanese encephalitis patients
  186. Entry into Cells and Selective Degradation of tRNAs by a Cytotoxic Member of the RNase A Family
  187. Induction of Nitric Oxide Synthase during Japanese Encephalitis Virus Infection: Evidence of Protective Role
  188. Antiviral effect of nitric oxide during Japanese encephalitis virus infection
  189. Regulation of intestinal regeneration: New insights
  190. Interferon Enhances the Activity of the Anticancer Ribonuclease, Onconase
  191. Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction
  192. Isolation of Desulfovibrio intestinalis sp. nov. from the hindgut of the lower termite Mastotermes darwiniensis
  193. Degradation of Japanese encephalitis virus by neutrophils
  194. Role of Organized Intestinal Lymphoid Aggregates in Intestinal Regeneration
  195. Inhibition of HIV-1 Production and Selective Degradation of Viral RNA by an Amphibian Ribonuclease
  196. Role of the N Terminus in RNase A Homologues: Differences in Catalytic Activity, Ribonuclease Inhibitor Interaction and Cytotoxicity
  197. A Study of the Intracellular Routing of Cytotoxic Ribonucleases
  198. Epithelial cell proliferation and biodistribution of radiolabeled urogastrone in the gastrointestinal mucosa of young and old mice
  199. Lignocellulose degradation by microorganisms from termite hills and termite guts: A survey on the present state of art
  200. Effect of systematic interleukin-3 administration on epithelial cell proliferation in mouse intestine
  201. Extent and Role of Urogastrone in the Adaptive Response of Rat Intestine to Patching of a Surgical Defect in the Ileum
  202. Ultrastructural studies of the termite (Odontotermes obesus) gut microflora and its cellulolytic properties
  203. Association of radiolabeled urogastrone binding with regenerating intestinal mucosa and epidermal growth factor/ urogastrone producing organs in rat
  204. Effect of cobalt and nickel on growth and carboxymethyl cellulase activity ofCellulomonas spp
  205. Production and localisation of carboxymethylcellulase, xylanase and ?-glucosidase fromCellulomonas andMicrococcus spp.
  206. The Effect of Intestinal Resection and Urogastrone on Intestinal Regeneration
  207. Ethanol Has Direct Inhibitory Effects on Steroidogenesis in Human Granulosa Cells: Specific Inhibition of LH Action
  208. Effect of age on intestinal regeneration in the rabbit
  209. Effect of Eflorithine on Intestinal Regeneration